✦ LIBER ✦

Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy

✍ Scribed by Avi I. Einzig; Peter H. Wiernik; Scott Wadler; Jerry Kaplan; Laura T. Benson; Laura Tentoramano; Valiant Tan

Book ID: 110231215
Publisher: Springer US
Year: 1998
Tongue: English
Weight: 91 KB
Volume: 16
Category: Article
ISSN: 0167-6997
DOI: 10.1023/a:1006004809169

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Fludarabine and granulocyte colony-stimu

Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia

✍ O’Brien, S; Kantarjian, H; Beran, M; Koller, C; Talpaz, M; Lerner, S; Keating, M 📂 Article 📅 1997 🏛 Nature Publishing Group 🌐 English ⚖ 215 KB

Phase I trial of mitoxantrone and granul

Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies

✍ Joan H. Schiller; Barry Storer; Rhoda Arzoomanian; Kendra Tutsch; Dona Alberti; 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 806 KB

Phase I study of escalating doses of mit

Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support

✍ Gini F. Fleming; Linda Janisch; Nicholas J. Vogelzang; Everett E. Vokes; Mark J. 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB 👁 2 views

## BACKGROUND. Both paclitaxel and mitoxantrone demonstrate significant antineoplastic activity in breast cancer patients. Colony stimulating factor support allows significant dose escalation of each of these drugs when administered as a single agent. ## METHODS. We performed a Phase I study empl

A phase I trial of ifosfamide and paclit

A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors

✍ Craig A. Bunnell; Lynn Thompson; Lori Buswell; Ross Berkowitz; Michael Muto; Ell 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Background: Ifosfamide and paclitaxel are antineoplastic agents with broad activity and with different mechanisms of action. a phase i trial was conducted to determine the maximum tolerated dose and associated toxicities of these agents when used in combination. ## Methods: Patients with refra

Phase I study of mitozantrone, methotrex

Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer

✍ O'Brien, MER; Nicolson, M; Montes, A; Tidy, A; Ashley, S; Powles, TJ 📂 Article 📅 1994 🏛 Nature Publishing Group 🌐 English ⚖ 706 KB

High-dose ifosfamide with mesna and gran

High-dose ifosfamide with mesna and granuloctye–colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma : A Southwest Oncology Group study

✍ Susan M. Talbot; Cathryn Rankin; Robert N. Taub; Stanley P. Balcerzak Jr.; Nirma 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

## Abstract ## BACKGROUND The current study was conducted to assess the activity and toxicity of high‐dose ifosfamide and mesna with recombinant human granulocyte–colony‐stimulating factor (rhG‐CSF), given in an outpatient setting, in the treatment of patients with unresectable malignant mesotheli